Med24
clinical-research 19. 10. 2026 • 2 min read • ClinicalTrials.gov (The University of Hong Kong)

Effect of Nurse-supported Mobile App for Self-help Cognitive Behavioral Therapy for Insomnia in Informal Cancer Caregivers: a Randomized Controlled Trial

This mixed-methods randomized controlled trial investigates whether a nurse-supported mobile app for self-help cognitive behavioral therapy for insomnia (CBT-I) effectively reduces insomnia severity among informal cancer caregivers, compared to sleep hygiene education.\ \ The primary research question is:\ Does...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This randomized controlled trial investigates the effect of a nurse-supported mobile app for self-help cognitive behavioral therapy for insomnia (CBT-I) on insomnia severity in informal cancer caregivers, compared to sleep hygiene education. The study enrolled 208 participants who were randomly assigned to one of two groups.

Study Design and Intervention

One group received a 6-week CBT-I program delivered via a WeChat mini program, accompanied by weekly nurse support sessions (up to 20 minutes each). The other group received sleep hygiene education, consisting of a one-page handout delivered via WeChat. Participants in both groups completed assessments at baseline, post-intervention, and 3-month follow-up. Assessments measured changes in insomnia severity as the primary outcome, alongside secondary outcomes including subjective sleep outcomes, psychological well-being, caregiver burden, fatigue, health-related quality of life, and participant acceptability and satisfaction.

Sponsored content

Research Methodology and Oversight

The research question addresses whether the nurse-supported mobile app for self-help CBT-I lowers insomnia severity among cancer caregivers compared to sleep hygiene education at post-intervention and 3-month follow-up. As part of the study design, a process evaluation will be conducted in alignment with the Medical Research Council (MRC) guidance, focusing on implementation, mechanisms of impact, and context. Following the 3-month follow-up assessment, participants in the sleep hygiene education group will have access to the CBT-I WeChat mini program.

Original Scientific Source
ClinicalTrials.gov (The University of Hong Kong)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation
clinical-research

Evaluation of the Espansione Equinox System Safety & Effectiveness for the Treatment of Meibomian Gland Dysfunction: A Prospective, Multicenter, Randomized Controlled Investigation

The purpose of this study is to demonstrate the non-inferiority of the Equinox System with respect to iLux 2020. Approximately 120 participants are expected to take part in the research trial at a minimum of three (3) and up to five (5) sites across the United States. The expected duration of the study will be six (6)...

16. 11. 2026 Read article →
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C
clinical-research

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant C

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

16. 11. 2026 Read article →
Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity
clinical-research

Comparison of Clinical Outcomes Associated With Different Transcranial Magnetic Stimulation Protocols Combined With Botulinum Toxin-A Injection in Post-Stroke Upper Limb Spasticity

Post-stroke upper limb spasticity is an important condition that negatively affects motor recovery, upper limb functions, and activities of daily living. Multimodal treatment approaches are recommended in the management of spasticity. In recent years, the effects of transcranial magnetic stimulation (TMS) on upper...

10. 11. 2026 Read article →
A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
clinical-research

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

This phase I/II trial studies the side effects and best dose of CPX-351 in combination with quizartinib for the treatment of acute myeloid leukemia and high risk myelodysplastic syndrome. CPX-351, composed of chemotherapy drugs daunorubicin and cytarabine, works in different ways to stop the growth of cancer cells,...

10. 11. 2026 Read article →
Advertisement